At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 62 enrolled
Drug / intervention
Carfilzomibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
In Brief
A Phase 2 clinical trial evaluating Carfilzomib for Neuroendocrine Cancer. Completed, enrolled 62 participants across 10 sites.
Detailed Summary
The purpose of this study is to determine if carfilzomib is safe and effective in the treatment of patients with advanced neuroendocrine tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroendocrine Cancer
CountriesUnited States
CollaboratorsAmgen
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartJul 2015
Primary CompletionMay 2021
TodayJul 2026
First PostedDec 17, 2014
Enrollment StartJul 15, 2015
Primary CompletionMay 15, 2021
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 11.5 years ago
Interventions
Carfilzomibdrug